Policy & Regulation
Avacta reports tumour shrinkage and 90% disease control rate for AVA6000 in salivary gland cancer patients
17 December 2025 - Biopharmaceutical company Avacta Therapeutics (AIM: AVCT) on Wednesday reported positive preliminary Phase 1b data for faridoxorubicin (AVA6000) in patients with salivary gland canc...
Galderma reports data showing rapid itch and sleep improvement with nemolizumab in dermatitis conditions
17 December 2025 - Dermatology specialist Galderma (SWX:GALD) on Wednesday reported new clinical data showing that Nemluvio (nemolizumab) can deliver rapid relief of itch and sleep disturbance as earl...
Sanofi's efdoralprin alfa receives EU orphan designation for AATD-related emphysema
17 December 2025 - French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced late Tuesday that the European Medicines Agency has granted orphan designation to efdoralprin alfa ...
Alcami completes third sterile fill-finish line at Research Triangle Park, NC
17 December 2025 - US-based based contract development and manufacturing organisation (CDMO) Alcami Corporation announced on Tuesday the GMP readiness of a third sterile fill-finish line at its Resear...
Black Buffalo partners with Sanova to support regulatory strategy and scientific innovation
17 December 2025 - Smokeless tobacco alternatives company Black Buffalo Inc announced on Tuesday that it has partnered with Sanova LLC, a New York-based scientific and regulatory consulting agency, to...
Neurocrine Biosciences reveals new chapter in R&D strategy
17 December 2025 - Neuroscience-focused biopharmaceutical company Neurocrine Biosciences Inc (Nasdaq:NBIX) on Tuesday announced a new chapter in its research and development strategy aimed at accelera...